Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naive to Methotrexate and Have Poor Prognostic Factors

Next Previous
Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naive to Methotrexate and Have Poor Prognostic Factors

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms C-OPERA
  • Sponsors Astellas Pharma; Otsuka Pharmaceutical; UCB Japan

Most Recent Events

  • 02 Feb 2017 Two-year results published in the Annals of the Rheumatic Diseases.
  • 20 Nov 2015 According to Astellas Pharma media release, results from this trial were presented at 2015 American College Of Rheumatology (ACR/ARHP) Annual Meeting.
  • 21 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top